Electrical field therapy with reduced histopathological change in muscle
First Claim
1. A method for reducing inducement of histopathological change in a target muscle tissue site resulting from application of an electric field to a subject to deliver a therapeutic agent thereto, said method comprising:
- introducing an effective amount of at least one therapeutic agent into the target muscle tissue site of a subject;
generating an electric field at the target muscle tissue site of the subject by introducing from 1 to about 4 monopolar DC pulses, each pulse having a duration of about 10 ms to about 100 ms, to generate a nominal field strength of about 100V/cm to about 300V/cm at the target muscle tissue site, thereby reducing the inducement of histopathological change in the target muscle tissue site resulting from application of the electric field as compared to alternative methods for applying an electric field to the target muscle tissue site.
1 Assignment
0 Petitions
Accused Products
Abstract
In vivo methods are provided for using an electric field to delivery therapeutic treatment to a subject while reducing inducement of histopathological change in the target muscle tissue, such as is associated with induction or amplification of an immune response caused by the pulsed electric field. Therapeutic agents can be delivered nto cells of muscle for local and systemic treatments with optimal gene expression and minimal tissue damage. In particular, therapeutic agents include naked or formulated nucleic acid, polypeptides and chemotherapeutic agents.
198 Citations
38 Claims
-
1. A method for reducing inducement of histopathological change in a target muscle tissue site resulting from application of an electric field to a subject to deliver a therapeutic agent thereto, said method comprising:
-
introducing an effective amount of at least one therapeutic agent into the target muscle tissue site of a subject;
generating an electric field at the target muscle tissue site of the subject by introducing from 1 to about 4 monopolar DC pulses, each pulse having a duration of about 10 ms to about 100 ms, to generate a nominal field strength of about 100V/cm to about 300V/cm at the target muscle tissue site, thereby reducing the inducement of histopathological change in the target muscle tissue site resulting from application of the electric field as compared to alternative methods for applying an electric field to the target muscle tissue site. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. An in vivo method for enhancing expression of a therapeutic polypeptide encoded by a isolated polynucleotide to be delivered into cells in a subject, said method comprising:
-
a) introducing an effective amount of at least one isolated polynucleotide encoding a therapeutic polypeptide into a target muscle tissue site of a subject; and
b) generating an electric field at the target muscle tissue site by introducing from 1 to about 4 monopolar DC pulses, each having a pulse duration of about 10 to about 100 ms, to generate a nominal field strength of about 100V/cm to about 300V/cm at the target muscle tissue site, at substantially the same time as the introduction of the polynucleotide so as to result in the polynucleotide entering cells of the target muscle tissue for expression of the therapeutic polypeptide therein;
thereby enhancing the expression of the therapeutic polypeptide as compared to expression of the therapeutic polypeptide achieved by other methods for generating an electric field in the target muscle tissue. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
-
-
37. A method for delivering a polynucleotide encoding a polypeptide to a target muscle tissue site comprising:
-
a) introducing an effective amount of at least one isolated polynucleotide encoding a polypeptide into a target muscle tissue site of a subject;
b) introducing at least a conductive portion of an electrode needle array into the target muscle tissue site; and
c) applying from 1 to about 4 monopolar DC pulses having a duration of about 10 ms to about 100 ms each to generate a nominal field strength of about 100V/cm to about 300V/cm at the target muscle site;
thereby delivering the polynucleotide to the target muscle. - View Dependent Claims (38)
-
Specification